What's New
Updated by Prof Bruce Campbell, University of Melbourne, for 2022 use. Added information about new DOAC reversal agents. Helpful for management of stroke, peri-operative care and other decisions involving DOAC use.
App Description
This application is for medical practitioners who need to quickly review which anticoagulant (including the direct oral anticoagulants (DOACs)) to use to prevent stroke in patients with non-valvular atrial fibrillation (NVAF).
It contains relevant information about warfarin, apixaban, dabigatran, rivaroxaban and edoxaban.
Topics covered include: comparison of anticoagulants, patient information, when anticoagulation is required, risk-benefit issues, when warfarin is appropriate, how to choose the dose of a DOAC, starting or switching between anticoagulants, edoxban information, clinical monitoring, bleeding risks, use of antiplatelet agents in addition to oral anticoagulants, managing ischemic strokes on DOACs, reversing anticoagulation in the event of intracerebral haemorrhage, a Cookcroft-Gault creatinine clearance calculator and peri-operative management information.
Information contained within the application was edited by Dr Bruce Campbell. Coding was by CereScape (www.cerescape.com). It is our aim to keep this information current, and we welcome constructive comments and evidenced updated information. Any profit generated by this application will be used to fund stroke research.
iPhone Screenshots
(click to enlarge)
iPad Screenshots
(click to enlarge)
App Changes
- November 27, 2013 Initial release
- December 17, 2013 New version 1.0.1
- February 18, 2015 New version 1.0.2
- July 13, 2016 New version 1.0.3
- December 05, 2016 New version 1.04
- January 22, 2020 New version 1.0.7
- July 15, 2020 New version 1.1.1
- December 10, 2020 New version 1.2.0
- September 16, 2023 New version 1.3
Other Apps From CereScape Pty Ltd
